Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) Shorts Decreased By 17.44% As Of Jun 27, 2018

June 27, 2018 - By Daniel Mitchell

Vascular Biogenics Ltd. (NASDAQ:VBLT) Corporate Logo

Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) noted a decrease of 17.44% in shorted shares. FINRA published shorted shares of VBLT’s total 436,600 shares. That’s 17.44% down from 528,800 shares. 4 days will cost VBLT with 116,500 average volume to recover its previous position. 3.07% is Vascular Biogenics LTD. – Ordinary Shares float short.

VBLT is hitting $2.3 during the last trading session, after decreased 1.08%.Vascular Biogenics Ltd. has volume of 30,895 shares. Since June 27, 2017 VBLT has declined 60.91% and is downtrending. VBLT underperformed the S&P 500 by 73.48%.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer.The firm is valued at $68.76 million. The company??s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.Currently it has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

In total 4 analysts cover Vascular Biogenics (NASDAQ:VBLT). “Buy” rating has 0, “Sell” are 0, while 4 are “Hold”. (NASDAQ:VBLT) has 0 bullish analysts. 6 are the (NASDAQ:VBLT)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. In Thursday, March 8 report H.C. Wainwright downgraded the stock to “Neutral” rating. On Thursday, March 22 the stock has “Hold” rating by H.C. Wainwright. On Friday, March 9 the stock has “Neutral” rating by Chardan Capital Markets. On Thursday, March 8 the company was downgraded by Piper Jaffray. On Thursday, March 8 the stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) earned “Hold” rating by JMP Securities. On Friday, May 18 the company was maintained by H.C. Wainwright.

For more Vascular Biogenics Ltd. (NASDAQ:VBLT) news published briefly go to: Streetinsider.com, Streetinsider.com, Nasdaq.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Pre-Open Movers 06/06: (AXON) (VBLT) (SIG) Higher; (AMBA) (IMGN) (OLLI) Lower (more…)” published on June 06, 2018, “VBL Therapeutics (VBLT) Presents Positive Data on its MOSPD2 Platform Technology” on June 05, 2018, “VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market” with a publish date: June 26, 2018, “VBL Therapeutics +42% after presenting data on MOSPD2 platform” and the last “40 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 26, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: